TherapeuticsMD (TXMD) Total Non-Current Liabilities (2012 - 2026)

TherapeuticsMD (TXMD) has 11 years of Total Non-Current Liabilities data on file, last reported at $9.7 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 9.03% year-over-year to $9.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.7 million (down 9.03% YoY) and the FY2025 annual result came in at $9.9 million, down 7.48% from the prior year.
• Total Non-Current Liabilities retreated to $9.7 million in Q1 2026, from $9.9 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $272.7 million in Q1 2022 to a low of $9.7 million in Q1 2026.
• A 5-year average of $50.6 million and a median of $12.8 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities sank 90.29% — and 2025, when it decreased 7.48%.
• Tracing TXMD's Total Non-Current Liabilities over 5 years: stood at $54.2 million in 2022, then slumped by 75.31% to $13.4 million in 2023, then decreased by 20.01% to $10.7 million in 2024, then slipped by 7.48% to $9.9 million in 2025, then slipped by 1.74% to $9.7 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $9.7 million (Q1 2026), $9.9 million (Q4 2025), and $10.4 million (Q3 2025), per Business Quant data.